CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM091915
035-os BibID:(WoS)000562771200009 (Scopus)85089407724
Első szerző:DiNardo, Courtney D.
Cím:Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia / C. D. DiNardo, B. A. Jonas, V. Pullarkat, M. J. Thirman, J. S. Garcia, A. H. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, J. Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R. M. Lemoli, K. Yamamoto, S.-S. Yoon, J. H. Jang, Su-Peng Yeh, M. Turgut, Wan-Jen Hong, Y. Zhou, J. Potluri, K. W. Pratz
Dátum:2020
ISSN:0028-4793
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:New England Journal Of Medicine. - 383 : 7 (2020), p. 617-629. -
További szerzők:Jonas, Brian A. Pullarkat, Vinod Thirman, Michael J. Garcia, Jacqueline S. Wei, Andrew H. Konopleva, Marina Döhner, Hartmut Letai, Anthony Fenaux, Pierre Koller, Elizabeth Havelange, Violaine Leber, Brian Esteve, Jordi Wang, Jianxiang Pejsa, Vlatko Hájek, Roman Porkka, Kimmo Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Lavie, David Lemoli, Roberto M. Yamamoto, Kazuhito Yoon, Sung-Soo Jang, Jun Ho Yeh, Su-Peng Turgut, Mehmet Hong, Wan-Jen Zhou, Ying Potluri, Jalaja Pratz, Keith W.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM120740
035-os BibID:(Scopus)85122922204 (WOS)000755659500008
Első szerző:Horwitz, Steven
Cím:The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma / S. Horwitz, O. A. O`Connor, B. Pro, L. Trümper, S. Iyer, R. Advani, N. L. Bartlett, J. H. Christensen, F. Morschhauser, E. Domingo-Domenech, G. Rossi, W. S. Kim, T. Feldman, T. Menne, D. Belada, Á. Illés, K. Tobinai, K. Tsukasaki, S.-P. Yeh, A. Shustov, A. Hüttmann, K. J. Savage, S. Yuen, P. L. Zinzani, H. Miao, V. Bunn, K. Fenton, M. Fanale, M. Puhlmann, T. Illidge
Dátum:2022
ISSN:0923-7534 1569-8041
Megjegyzések:Background: For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. Patients and methods: ECHELON-2 is a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase III study. We present an exploratory update of the ECHELON-2 study, including an analysis of 5-year PFS per investigator in the intent-to-treat analysis group. Results: A total of 452 patients were randomized (1 : 1) to six or eight cycles of A+CHP (N = 226) or CHOP (N = 226). At median follow-up of 47.6 months, 5-year PFS rates were 51.4% [95% confidence interval (CI): 42.8% to 59.4%] with A+CHP versus 43.0% (95% CI: 35.8% to 50.0%) with CHOP (hazard ratio = 0.70; 95% CI: 0.53-0.91), and 5-year overall survival (OS) rates were 70.1% (95% CI: 63.3% to 75.9%) with A+CHP versus 61.0% (95% CI: 54.0% to 67.3%) with CHOP (hazard ratio = 0.72; 95% CI: 0.53-0.99). Both PFS and OS were generally consistent across key subgroups. Peripheral neuropathy was resolved or improved in 72% (84/117) of patients in the A+CHP arm and 78% (97/124) in the CHOP arm. Among patients who relapsed and subsequently received brentuximab vedotin, the objective response rate was 59% with brentuximab vedotin retreatment after A+CHP and 50% with subsequent brentuximab vedotin after CHOP. Conclusions: In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
brentuximab vedotin
CHOP
frontline treatment
overall survival
peripheral T-cell lymphoma
randomized clinical trial
Megjelenés:Annals Of Oncology. - 33 : 3 (2022), p. 288-298. -
További szerzők:O'Connor, Owen A. Pro, Barbara Trümper, Lorenz Iyer, Swaminathan Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won-Seok Feldman, Tatyana Menne, T. Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Zinzani, Pier Luigi Miao, Harry Bunn, V. Fenton, Keenan Fanale, Michelle Puhlmann, M. Illidge, Tim
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM077363
035-os BibID:(WoS)000456000000026 (Scopus)85059506213
Első szerző:Horwitz, Steven
Cím:Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial / Steven Horwitz, Owen A. O'Connor, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, ECHELON-2 Study Group
Dátum:2019
ISSN:2352-3026
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:The Lancet Haematology. - 393 : 10168 (2019), p. 229-240. -
További szerzők:O'Connor, Owen A. Illidge, Tim Fanale, Michelle Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won Seog Feldman, Tatyana Lennard, Anne Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Iyer, Swaminathan Zinzani, Pier Luigi Hua, Zhaowei Little, Meredith Rao, Shangbang Woolery, Joseph Manley, Thomas Trümper, Lorenz ECHELON-2 Study Group
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

4.

001-es BibID:BIBFORM119187
035-os BibID:(Scopus)85185111057 (WoS) 001240529600001
Első szerző:Pratz, Keith W.
Cím:Long-term follow-up of VIALE-A : Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia / Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Hartmut Döhner, Christian Récher, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Arpád Illés, Roberto M. Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo
Dátum:2024
ISSN:0361-8609 1096-8652
Megjegyzések:Venetoclax-azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE-A study (NCT02993523). Here, long-term follow-up is presented to address survival benefit and long-term outcomes with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azacitidine or placebo-azacitidine. OS was the primary endpoint; complete remission with/without blood count recovery (CR/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE-A, 431 patients were enrolled to venetoclax-azacitidine (n = 286) or placebo-azacitidine (n = 145). At 43.2 months median follow-up, median OS was 14.7 months (95% confidence interval [CI], 12.1?18.7) with venetoclax-azacitidine, and 9.6 months (95% CI, 7.4-12.7) with placebo-azacitidine (hazard ratio, 0.58 [95% CI, 0.47?0.72], p <.001); the estimated 24-month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with IDH1/2 mutations and those with measurable residual disease responses was reached in this final analysis. CR/CRi rate was similar to interim analysis. Any-grade hematologic and gastrointestinal adverse events were most common in venetoclax-azacitidine and placebo-azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long-term efficacy and safety confirm venetoclax-azacitidine is an improvement in standard-of-care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:American Journal Of Hematology. - 99 : 4 (2024), p. 615-624. -
További szerzők:Jonas, Brian A. Pullarkat, Vinod Thirman, Michael J. Garcia, Jacqueline S. Döhner, Hartmut Recher, Christian Fiedler, Walter Yamamoto, Kazuhito Wang, Jianxiang Yoon, Sung-Soo Wolach, Ofir Yeh, Su-Peng Leber, Brian Esteve, Jordi Mayer, Jiri Porkka, Kimmo Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Lemoli, Roberto M. Turgut, Mehmet Ku, Grace Miller, Catherine Zhou, Ying Zhang, Meng Chyla, Brenda Potluri, Jalaja DiNardo, Courtney D.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM100442
035-os BibID:(WoS)000765922300008 (Scopus)85125966990
Első szerző:Pratz, Keith W.
Cím:Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine / Pratz Keith W., Jonas Brian A., Pullarkat Vinod, Recher Christian, Schuh Andre C., Thirman Michael J., Garcia Jacqueline S., DiNardo Courtney D., Vorobyev Vladimir, Fracchiolla Nicola S., Yeh Su-Peng, Jang Jun Ho, Ozcan Muhit, Yamamoto Kazuhito, Illes Arpad, Zhou Ying, Dail Monique, Chyla Brenda, Potluri Jalaja, Döhner Hartmut
Dátum:2022
ISSN:0732-183X 1527-7755
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Clinical Oncology. - 40 : 8 (2022), p. 855-865. -
További szerzők:Jonas, Brian A. Pullarkat, Vinod Recher, Christian Schuh, Andre C. Thirman, Michael J. Garcia, Jacqueline S. DiNardo, Courtney D. Vorobyev, Vladimir Fracchiolla, Nicola S. Yeh, Su-Peng Jang, Jun Ho Ozcan, Muhit Yamamoto, Kazuhito Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Zhou, Ying Dail, Monique Chyla, Brenda Potluri, Jalaja Döhner, Hartmut
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.